ATLANTIC-PRIMATES: a dataset of communities and occurrences of primates in the Atlantic Forests of South America

Primates play an important role in ecosystem functioning and offer critical insights into human evolution, biology, behavior, and emerging infectious diseases. There are 26 primate species in the Atlantic Forests of South America, 19 of them endemic. We compiled a dataset of 5,472 georeferenced locations of 26 native and 1 introduced primate species, as hybrids in the genera Callithrix and Alouatta. The dataset includes 700 primate communities, 8,121 single species occurrences and 714 estimates of primate population sizes, covering most natural forest types of the tropical and subtropical Atlantic Forest of Brazil, Paraguay and Argentina and some other biomes. On average, primate communities of the Atlantic Forest harbor 2 ± 1 species (range = 1–6). However, about 40% of primate communities contain only one species. Alouatta guariba (N = 2,188 records) and Sapajus nigritus (N = 1,127) were the species with the most records. Callicebus barbarabrownae (N = 35), Leontopithecus caissara (N = 38), and Sapajus libidinosus (N = 41) were the species with the least records. Recorded primate densities varied from 0.004 individuals/km 2 (Alouatta guariba at Fragmento do Bugre, Paraná, Brazil) to 400 individuals/km 2 (Alouatta caraya in Santiago, Rio Grande do Sul, Brazil). Our dataset reflects disparity between the numerous primate census conducted in the Atlantic Forest, in contrast to the scarcity of estimates of population sizes and densities. With these data, researchers can develop different macroecological and regional level studies, focusing on communities, populations, species co-occurrence and distribution patterns. Moreover, the data can also be used to assess the consequences of fragmentation, defaunation, and disease outbreaks on different ecological processes, such as trophic cascades, species invasion or extinction, and community dynamics. There are no copyright restrictions. Please cite this Data Paper when the data are used in publications. We also request that researchers and teachers inform us of how they are using the data. © 2018 by the The Authors. Ecology © 2018 The Ecological Society of Americ

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed

Avaliação da expansão de células estromais mesenquimais em biorreator de fibra oca

The use of mesenchymal stromal cells (MSCs) for clinical therapy has been limited by the low amount of cells that can be obtained directly from tissue, making it necessary to develop techniques for in vitro cell number expansion. The current methods of expansion are laborintensive, exhibit unfavorable environments for cell growth, show still modest levels of expansion and low yield in the recovery of these cells. In the search for better alternatives, several types of bioreactors have been assessed, however, with results still discreet. A littlestudied system, which has showed itself very effective in the use with other types of animal cells, is the hollow fiber bioreactor. This bioreactor has relatively homogeneous culture environment, low level of hydrodynamic stress on cells and the process control is made through manipulation external to the culture. Thus, it is proposed in this work the study of the in vitro expansion of MSCs in 15 mL hollow fiber prototype bioreactor designed and built with a configuration specifically conceived for expansion of MSCs for use in therapeutic applications. The inoculum was prepared with MSCs precultured adhered to microcarrier Cultispher-S at concentration of 4 g/L in spinner flask containing 50 mL of α-MEM culture medium with 15% v/v fetal bovine serum. The preculture was performed in CO2 incubator at pH close to 7.3 and temperature of 37°C. For bioreactor expansion cultures, it was used the same culture medium, with addition of 12 g/L of alginate and 4.25-4.50 mM of CaCl2 as gelling agents to immobilize and keep in suspension the microcarriers, in the conditions of pH and temperature used in the preculture. The oxygenation of the culture medium continuously recirculated through the intracapilar space was carried out by air bubbling in an external flask. The oxygenation levels were of 70 to 90% of saturation with air. The experimental results obtained show that the used configuration of hollow fiber bioreactor promoted good conditions for expansion of MSCs without cell aggregation, reaching 15.3-fold expansion and cell recovery levels of 82%. These results also demonstrate the possibility of improving the efficiency of MSCs expansion through the renewal of medium to maintain suitable levels of arginine, nutrient present in limiting amounts, and ammonium, growth inhibitor metabolite.Universidade Federal de Sao CarlosA utilização de células estromais mesenquimais (MSCs em inglês) para a terapia clínica tem sido limitada pela baixa quantidade de células que podem ser obtidas diretamente do tecido, tornando necessário o desenvolvimento de técnicas de expansão do número de células in vitro. Os métodos atuais de expansão apresentam necessidade de intensa mão de obra, ambientes desfavoráveis para o crescimento celular, níveis de expansão ainda modestos e baixo rendimento na recuperação destas células. Na procura de melhores alternativas, diversos tipos de biorreatores vêm sendo avaliados, porém, com resultados ainda discretos. Um sistema pouco estudado que tem se mostrado muito eficiente no uso com outros tipos de células animais é o biorreator de fibra oca. Este biorreator apresenta ambiente de cultura relativamente homogêneo, baixo nível de forças hidrodinâmicas sobre as células e o controle do processo é feito através de manipulação externa à cultura. Assim, é proposto neste trabalho o estudo da expansão in vitro de MSCs num protótipo de biorreator de fibra oca de 15 mL projetado e construído com uma configuração especialmente concebida para expansão de MSCs a serem utilizadas em aplicações terapêuticas. O inóculo foi preparado com MSCs précultivadas aderidas ao microcarregador Cultispher-S na concentração de 4 g/L em frasco spinner contendo 50 mL de meio de cultura α-MEM com 15% v/v de soro fetal bovino. O précultivo foi realizado em incubadora de CO2 a pH próximo a 7,3 e temperatura de 37°C. Para os cultivos de expansão no biorreator foi utilizado o mesmo meio de cultura, com adição de 12 g/L de alginato e 4,25-4,50 mM de CaCl2 como agentes geleificantes para imobilizar e manter suspensos os microcarregadores, nas condições de pH e temperatura utilizadas no précultivo. A oxigenação do meio de cultura continuamente recirculado pelo espaço intracapilar foi realizada mediante borbulhamento de ar em um frasco externo. Os níveis de oxigenação foram de 70 a 90% da saturação com ar. Os resultados experimentais obtidos mostram que a configuração utilizada propiciou boas condições para a expansão sem agregação celular das MSCs, chegando-se a fatores de expansão estimados de 15,3 vezes e níveis de recuperação de células de 82%. Esses resultados também evidenciam a possibilidade de melhora da eficiência da expansão das MSCs através da renovação do meio de cultivo para a manutenção de níveis adequados de arginina, nutriente presente em quantidades limitantes, e amônia, metabólito inibidor de crescimento

Feasibility of the taylor vortex flow bioreactor for mesenchymal stromal cell expansion on microcarriers

International audienc

Trabalhos completos - Administração

Trabalhos completos - Administraçã